Guérin Alain P, Pannier Bruno, Marchais Sylvain J, London Gérard M
Department of Haemodialysis, F.H. Manhès Hospital, Fleury-Mérogis, France.
Curr Opin Nephrol Hypertens. 2006 Mar;15(2):105-10. doi: 10.1097/01.mnh.0000203186.11772.21.
Cardiovascular disease is a major factor in the high mortality of patients with end-stage renal disease, and this population is particularly appropriate to analyse the impact of cardiovascular risk markers on outcome.
Cardiovascular risk markers in end-stage renal disease include age, left ventricular mass, carotid intima-media thickness, blood pressure and aortic stiffness (pulse wave velocity). Aortic pulse wave velocity has been shown to be an independent predictor of cardiovascular mortality in patients with end-stage renal disease and the general population. Aortic pulse wave velocity has the highest sensitivity and specificity as a predictor of cardiovascular death in end-stage renal disease patients. Pulse wave velocity is an integrated index of vascular function and structure, and is a major determinant of systolic hypertension, thereby increasing left ventricular afterload, left ventricular hypertrophy and left ventricular oxygen consumption. Decreased diastolic blood pressure, another consequence of arterial stiffening, is associated with decreased coronary perfusion contributing to ischaemic heart disease and evolution of adaptive into maladaptive left ventricular hypertrophy.
Aortic stiffness measurements could serve as an important tool in identifying end-stage renal disease patients at higher risk of cardiovascular disease. The ability to identify these patients would lead to better risk stratification and earlier and more cost-effective preventive therapy.
心血管疾病是终末期肾病患者高死亡率的主要因素,这一人群特别适合分析心血管风险标志物对预后的影响。
终末期肾病的心血管风险标志物包括年龄、左心室质量、颈动脉内膜中层厚度、血压和主动脉僵硬度(脉搏波速度)。主动脉脉搏波速度已被证明是终末期肾病患者和普通人群心血管死亡率的独立预测指标。在终末期肾病患者中,主动脉脉搏波速度作为心血管死亡预测指标具有最高的敏感性和特异性。脉搏波速度是血管功能和结构的综合指标,是收缩期高血压的主要决定因素,从而增加左心室后负荷、左心室肥厚和左心室氧耗。动脉僵硬度的另一个后果是舒张压降低,这与冠状动脉灌注减少有关,导致缺血性心脏病以及适应性左心室肥厚向失代偿性左心室肥厚的演变。
主动脉僵硬度测量可作为识别心血管疾病高风险终末期肾病患者的重要工具。识别这些患者的能力将导致更好的风险分层以及更早且更具成本效益的预防性治疗。